Area of research
Economics and Econometrics · Immunology
Research interest
Research interests include Medicine, Biosimilar, Business, Reimbursement, Endometriosis, and Intensive care medicine.
Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review
Evaluating the Cost-Effectiveness of Air Pollution Mitigation Strategies: A Systematic Review
Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study
A health economic guide to market access of biosimilars
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
Development and implementation of “Check of Medication Appropriateness” (CMA): advanced pharmacotherapy-related clinical rules to support medication surveillance
Nanomedicines: The magic bullets reaching their target?
Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review
Policies for biosimilar uptake in Europe: An overview
The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
8th European Conference on Rare Diseases & Orphan Products (ECRD 2016)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Quality of life outcomes in women with endometriosis are highly influenced by recruitment strategies
Rare diseases and effective treatments: are we delivering?